Centessa Pharmaceuticals (NASDAQ:CNTA) Now Covered by Analysts at Wolfe Research

Equities research analysts at Wolfe Research initiated coverage on shares of Centessa Pharmaceuticals (NASDAQ:CNTA) in a report issued on Tuesday, MarketBeat Ratings reports. The firm set an “outperform” rating and a $40.00 price target on the stock. Wolfe Research’s target price points to a potential upside of 56.92% from the company’s previous close.

A number of other research analysts have also commented on CNTA. B. Riley Financial raised their price target on Centessa Pharmaceuticals from $33.00 to $42.00 and gave the company a “buy” rating in a report on Monday, December 1st. Truist Financial boosted their price target on shares of Centessa Pharmaceuticals from $33.00 to $38.00 and gave the stock a “buy” rating in a research report on Thursday, January 29th. Stephens initiated coverage on Centessa Pharmaceuticals in a report on Tuesday, October 28th. They set an “overweight” rating and a $35.00 target price on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a report on Wednesday, January 21st. Finally, Wall Street Zen upgraded shares of Centessa Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, October 27th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Centessa Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $38.64.

Centessa Pharmaceuticals Stock Performance

Shares of CNTA stock opened at $25.49 on Tuesday. Centessa Pharmaceuticals has a 12-month low of $9.60 and a 12-month high of $30.58. The company has a debt-to-equity ratio of 0.36, a current ratio of 10.56 and a quick ratio of 10.57. The firm has a market capitalization of $3.72 billion, a price-to-earnings ratio of -13.93 and a beta of 1.56. The business has a 50 day simple moving average of $24.23 and a 200 day simple moving average of $23.40.

Insider Transactions at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, insider Iqbal J. Hussain sold 38,951 shares of Centessa Pharmaceuticals stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $25.15, for a total transaction of $979,617.65. Following the transaction, the insider owned 57,645 shares of the company’s stock, valued at $1,449,771.75. The trade was a 40.32% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Mario Alberto Accardi sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $30.00, for a total transaction of $300,000.00. Following the sale, the insider owned 178,801 shares of the company’s stock, valued at approximately $5,364,030. This represents a 5.30% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 49,961 shares of company stock valued at $1,304,878 over the last 90 days. Corporate insiders own 7.09% of the company’s stock.

Institutional Trading of Centessa Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. Avoro Capital Advisors LLC boosted its position in Centessa Pharmaceuticals by 34.7% during the fourth quarter. Avoro Capital Advisors LLC now owns 14,555,555 shares of the company’s stock valued at $364,034,000 after purchasing an additional 3,747,475 shares during the last quarter. Adage Capital Partners GP L.L.C. lifted its holdings in shares of Centessa Pharmaceuticals by 12.4% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 11,281,741 shares of the company’s stock valued at $282,156,000 after buying an additional 1,246,741 shares during the last quarter. Farallon Capital Management LLC grew its stake in shares of Centessa Pharmaceuticals by 24.1% in the 4th quarter. Farallon Capital Management LLC now owns 5,377,068 shares of the company’s stock valued at $134,480,000 after buying an additional 1,045,750 shares in the last quarter. Siren L.L.C. grew its position in Centessa Pharmaceuticals by 24.8% in the fourth quarter. Siren L.L.C. now owns 4,027,517 shares of the company’s stock worth $100,728,000 after acquiring an additional 800,000 shares in the last quarter. Finally, Commodore Capital LP boosted its holdings in Centessa Pharmaceuticals by 39.3% during the second quarter. Commodore Capital LP now owns 3,298,289 shares of the company’s stock valued at $43,340,000 after acquiring an additional 930,711 shares during the period. 82.01% of the stock is currently owned by hedge funds and other institutional investors.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.